These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23740824)

  • 41. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determinants of Perceived Health Nonimprovement in Early Rheumatoid Arthritis Patients With Favorable Treatment Outcomes.
    Steunebrink LMM; Oude Voshaar MAH; Taal E; Vonkeman HE; Zijlstra TR; van de Laar MAFJ
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):510-515. PubMed ID: 28622462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.
    Kekow J; Moots R; Khandker R; Melin J; Freundlich B; Singh A
    Rheumatology (Oxford); 2011 Feb; 50(2):401-9. PubMed ID: 21059675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era.
    Twigg S; Hensor EMA; Freeston J; Tan AL; Emery P; Tennant A; Morgan AW;
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):361-368. PubMed ID: 28511291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018.
    Xie W; Li J; Zhang X; Sun X; Zhang Z
    Int J Rheum Dis; 2019 Sep; 22(9):1670-1678. PubMed ID: 31297977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.
    Schulman E; Bartlett SJ; Schieir O; Andersen KM; Boire G; Pope JE; Hitchon C; Jamal S; Thorne JC; Tin D; Keystone EC; Haraoui B; Goodman SM; Bykerk VP;
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1185-1191. PubMed ID: 29193840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies.
    Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1600-6. PubMed ID: 25028381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life.
    Scott IC; Ibrahim F; Panayi G; Cope AP; Garrood T; Vincent A; Scott DL; Kirkham B;
    Semin Arthritis Rheum; 2019 Aug; 49(1):20-26. PubMed ID: 30685064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.
    Vermeer M; Kuper HH; Bernelot Moens HJ; Hoekstra M; Posthumus MD; van Riel PL; van de Laar MA
    Arthritis Res Ther; 2012 Nov; 14(6):R254. PubMed ID: 23176083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
    Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
    Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
    Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
    Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?
    Markusse IM; Dirven L; Han KH; Ronday HK; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
    Arthritis Care Res (Hoboken); 2015 May; 67(6):739-45. PubMed ID: 25581505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of patient-reported outcomes in the assessment of rheumatoid arthritis disease activity:the experience of the ESPOIR cohort.
    Che H; Combe B; Morel J; Cantagrel A; Gossec L; Lukas C
    Clin Exp Rheumatol; 2016; 34(4):646-54. PubMed ID: 27384748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account.
    Huscher D; Sengler C; Gromnica-Ihle E; Bischoff S; Eidner T; Ochs W; Richter J; Zink A
    Clin Exp Rheumatol; 2013; 31(2):256-62. PubMed ID: 23305590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Poor to modest agreement between rheumatoid arthritis response measures in clinical practice.
    Michaud K; Mikuls TR; Call SE; Reimold AM; Hooker R; Kerr GS; Richards JS; Caplan L; Cannon GW
    Clin Exp Rheumatol; 2009; 27(4):633-40. PubMed ID: 19772796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.